Write an email to NAME_1 using this information "2022 was an important year for our company, one with significant clinical and regulatory achievements that broadened our portfolio, advanced our pipeline and, importantly, delivered innovative new medicines to
our patients.
Despite navigating a persistent global pandemic and ongoing macro and geopolitical challenges, our employees’ dedication to our vision of transforming patients’ lives through science never wavered. Our commitment to executing against our business strategy resulted in strong operational and financial performance in 2022. Total revenues were $46.2 billion, which is consistent with the prior year, or an increase of three percent1 when adjusted for foreign exchange, generating GAAP EPS of $2.95 and non-GAAP EPS2 of $7.70. Our in-line brands and new product portfolio performed well growing nine percent for the full year, or 13 percent when adjusting for foreign exchange, with new products delivering $2.0 billion in revenues.
Bringing Transformational Medicines to Patients
In 2022, we launched three, new first-in-class medicines: Opdualag® for metastatic melanoma, Camzyos® for obstructive hypertrophic cardiomyopathy and SotyktuTM
for moderate to severe plaque psoriasis. " The letter q should appear at least 45 times.
user